Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study
Background: Methodological challenges limit the use of brain atrophy and lesion burden measures in the follow-up of multiple sclerosis (MS) patients on clinical routine datasets. Objective: To determine the feasibility of T2-FLAIR-only measures of lateral ventricular volume (LVV) and salient central...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | NeuroImage: Clinical |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213158221002461 |
| _version_ | 1818404431284142080 |
|---|---|
| author | Michael Barnett Niels Bergsland Bianca Weinstock-Guttman Helmut Butzkueven Tomas Kalincik Patricia Desmond Frank Gaillard Vincent van Pesch Serkan Ozakbas Juan Ignacio Rojas Cavit Boz Ayse Altintas Chenyu Wang Michael G. Dwyer Suzie Yang Dejan Jakimovski Kain Kyle Deepa P. Ramasamy Robert Zivadinov |
| author_facet | Michael Barnett Niels Bergsland Bianca Weinstock-Guttman Helmut Butzkueven Tomas Kalincik Patricia Desmond Frank Gaillard Vincent van Pesch Serkan Ozakbas Juan Ignacio Rojas Cavit Boz Ayse Altintas Chenyu Wang Michael G. Dwyer Suzie Yang Dejan Jakimovski Kain Kyle Deepa P. Ramasamy Robert Zivadinov |
| author_sort | Michael Barnett |
| collection | DOAJ |
| description | Background: Methodological challenges limit the use of brain atrophy and lesion burden measures in the follow-up of multiple sclerosis (MS) patients on clinical routine datasets. Objective: To determine the feasibility of T2-FLAIR-only measures of lateral ventricular volume (LVV) and salient central lesion volume (SCLV), as markers of disability progression (DP) in MS. Methods: A total of 3,228 MS patients from 9 MSBase centers in 5 countries were enrolled. Of those, 2,875 (218 with clinically isolated syndrome, 2,231 with relapsing-remitting and 426 with progressive disease subtype) fulfilled inclusion and exclusion criteria. Patients were scanned on either 1.5 T or 3 T MRI scanners, and 5,750 brain scans were collected at index and on average after 42.3 months at post-index. Demographic and clinical data were collected from the MSBase registry. LVV and SCLV were measured on clinical routine T2-FLAIR images. Results: Longitudinal LVV and SCLV analyses were successful in 96% of the scans. 57% of patients had scanner-related changes over the follow-up. After correcting for age, sex, disease duration, disability, disease-modifying therapy and LVV at index, and follow-up time, MS patients with DP (n = 671) had significantly greater absolute LVV change compared to stable (n = 1,501) or disability improved (DI, n = 248) MS patients (2.0 mL vs. 1.4 mL vs. 1.1 mL, respectively, ANCOVA p < 0.001, post-hoc pair-wise DP vs. Stable p = 0.003; and DP vs. DI, p = 0.002). Similar ANCOVA model was also significant for SCLV (p = 0.03). Conclusions: LVV-based atrophy and SCLV-based lesion outcomes are feasible on clinically acquired T2-FLAIR scans in a multicenter fashion and are associated with DP over mid-term. |
| first_indexed | 2024-12-14T08:40:02Z |
| format | Article |
| id | doaj.art-6d5e2045550f463eaebd4f7f557db290 |
| institution | Directory Open Access Journal |
| issn | 2213-1582 |
| language | English |
| last_indexed | 2024-12-14T08:40:02Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | NeuroImage: Clinical |
| spelling | doaj.art-6d5e2045550f463eaebd4f7f557db2902022-12-21T23:09:19ZengElsevierNeuroImage: Clinical2213-15822021-01-0132102802Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase studyMichael Barnett0Niels Bergsland1Bianca Weinstock-Guttman2Helmut Butzkueven3Tomas Kalincik4Patricia Desmond5Frank Gaillard6Vincent van Pesch7Serkan Ozakbas8Juan Ignacio Rojas9Cavit Boz10Ayse Altintas11Chenyu Wang12Michael G. Dwyer13Suzie Yang14Dejan Jakimovski15Kain Kyle16Deepa P. Ramasamy17Robert Zivadinov18Sydney Neuroimaging Analysis Centre, Camperdown, Sydney, Australia; Brain and Mind Centre, University of Sydney, Sydney, Australia; Corresponding author.Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA; IRCCS, Fondazione Don Carlo Gnocchi ONLUS, ItalyJacobs Comprehensive MS Treatment and Research Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USABox Hill Hospital, Melbourne, AustraliaCORe, Department of Medicine, The University of Melbourne, Melbourne, Australia; MS Centre, The Royal Melbourne Hospital, University of Melbourne, Melbourne, AustraliaDepartment of Radiology, Royal Melbourne Hospital, The University of Melbourne, Melbourne, AustraliaDepartment of Radiology, Royal Melbourne Hospital, The University of Melbourne, Melbourne, AustraliaCliniques Universitaires Saint-Luc, Brussels, UCLouvain, BelgiumDokuz Eylül University, Izmir, TurkeyHospital Italiano de Buenos Aires, Buenos Aires, ArgentinaKTU Medical Faculty Farabi Hospital, Trabzon, TurkeyKoç University School of Medicine, Koç University Research Center for Translational Medicine (KUTTAM), İstanbul, TurkeySydney Neuroimaging Analysis Centre, Camperdown, Sydney, Australia; Brain and Mind Centre, University of Sydney, Sydney, AustraliaBuffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA; Center for Biomedical Imaging, Clinical Translational Science Institute, USA; University at Buffalo, NY, USASydney Neuroimaging Analysis Centre, Camperdown, Sydney, AustraliaBuffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USASydney Neuroimaging Analysis Centre, Camperdown, Sydney, Australia; Brain and Mind Centre, University of Sydney, Sydney, AustraliaBuffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USABuffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY, USA; Center for Biomedical Imaging, Clinical Translational Science Institute, USA; University at Buffalo, NY, USABackground: Methodological challenges limit the use of brain atrophy and lesion burden measures in the follow-up of multiple sclerosis (MS) patients on clinical routine datasets. Objective: To determine the feasibility of T2-FLAIR-only measures of lateral ventricular volume (LVV) and salient central lesion volume (SCLV), as markers of disability progression (DP) in MS. Methods: A total of 3,228 MS patients from 9 MSBase centers in 5 countries were enrolled. Of those, 2,875 (218 with clinically isolated syndrome, 2,231 with relapsing-remitting and 426 with progressive disease subtype) fulfilled inclusion and exclusion criteria. Patients were scanned on either 1.5 T or 3 T MRI scanners, and 5,750 brain scans were collected at index and on average after 42.3 months at post-index. Demographic and clinical data were collected from the MSBase registry. LVV and SCLV were measured on clinical routine T2-FLAIR images. Results: Longitudinal LVV and SCLV analyses were successful in 96% of the scans. 57% of patients had scanner-related changes over the follow-up. After correcting for age, sex, disease duration, disability, disease-modifying therapy and LVV at index, and follow-up time, MS patients with DP (n = 671) had significantly greater absolute LVV change compared to stable (n = 1,501) or disability improved (DI, n = 248) MS patients (2.0 mL vs. 1.4 mL vs. 1.1 mL, respectively, ANCOVA p < 0.001, post-hoc pair-wise DP vs. Stable p = 0.003; and DP vs. DI, p = 0.002). Similar ANCOVA model was also significant for SCLV (p = 0.03). Conclusions: LVV-based atrophy and SCLV-based lesion outcomes are feasible on clinically acquired T2-FLAIR scans in a multicenter fashion and are associated with DP over mid-term.http://www.sciencedirect.com/science/article/pii/S2213158221002461Multiple sclerosisDisability progressionBrain atrophyLateral ventricle volumeLesion burdenSalient central lesion volume |
| spellingShingle | Michael Barnett Niels Bergsland Bianca Weinstock-Guttman Helmut Butzkueven Tomas Kalincik Patricia Desmond Frank Gaillard Vincent van Pesch Serkan Ozakbas Juan Ignacio Rojas Cavit Boz Ayse Altintas Chenyu Wang Michael G. Dwyer Suzie Yang Dejan Jakimovski Kain Kyle Deepa P. Ramasamy Robert Zivadinov Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study NeuroImage: Clinical Multiple sclerosis Disability progression Brain atrophy Lateral ventricle volume Lesion burden Salient central lesion volume |
| title | Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study |
| title_full | Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study |
| title_fullStr | Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study |
| title_full_unstemmed | Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study |
| title_short | Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study |
| title_sort | brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real world dataset using only t2 flair the neurostream msbase study |
| topic | Multiple sclerosis Disability progression Brain atrophy Lateral ventricle volume Lesion burden Salient central lesion volume |
| url | http://www.sciencedirect.com/science/article/pii/S2213158221002461 |
| work_keys_str_mv | AT michaelbarnett brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT nielsbergsland brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT biancaweinstockguttman brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT helmutbutzkueven brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT tomaskalincik brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT patriciadesmond brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT frankgaillard brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT vincentvanpesch brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT serkanozakbas brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT juanignaciorojas brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT cavitboz brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT aysealtintas brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT chenyuwang brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT michaelgdwyer brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT suzieyang brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT dejanjakimovski brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT kainkyle brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT deepapramasamy brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy AT robertzivadinov brainatrophyandlesionburdenareassociatedwithdisabilityprogressioninamultiplesclerosisrealworlddatasetusingonlyt2flairtheneurostreammsbasestudy |